Parsa Kiai, a director at Medifast Inc., purchased 661 shares of the company's common stock on November 4, 2026, for $8,609 at an average price of $13.0255 per share. The shares were acquired indirectly through Steamboat Capital Partners II, LP, of which Kiai serves as Managing Member of the general partner. Following the transaction, Kiai holds 21,089 shares of Medifast common stock indirectly.
The stock trades near $12.81 with a market cap of $132 million. Medifast reported third-quarter 2026 results that beat analyst expectations, posting an adjusted earnings loss of $0.19 per share versus the projected $0.62 loss. Revenue reached $72.05 million, topping the $67.7 million estimate. The company carries 69% gross profit margins but reported negative earnings of $3.69 per share over the last twelve months.
Investors tracking MED should monitor whether analyst sentiment shifts following the company's earnings beat and insider buying activity.